Media

News
Gadot Biochemical Industries Responds to FDA’s New Qualified Health Claims for Magnesium
13 Jan 2022
Ohad Cohen, chief executive officer of Israel-based Gadot Biochemical Industries (GBI), one of the world’s leading suppliers of magnesium and other minerals for dietary supplement and food fortification, has announced that the news of the FDA’s qualified health claim for magnesium is an excellent first step in recognition of magnesium’s abilities to promote cardio- and cerebrovascular health.
(HAIFA BAY, ISRAEL) Jan. 13, 2022 – Ohad Cohen, chief executive officer of Israel-based Gadot Biochemical Industries (GBI), one of the world’s leading suppliers of magnesium and other minerals for dietary supplement and food fortification, has announced that the news of the FDA’s qualified health claim for magnesium is an excellent first step in recognition of magnesium’s abilities to promote cardio- and cerebrovascular health. The FDA, in response to a petition submitted by The Center for Magnesium Education and Research LLC, has given permission for formulators using magnesium to clearly link the consumption of the mineral to reduced risk of high blood pressure. Regarding the qualified health claims are now allowed to appear on marketing materials for magnesium-containing supplements, foods, and beverages Cohen commented, “We are encouraged by the fact that the FDA recognizes that magnesium consumption can benefit human health via helping to support healthy blood pressure. It is an auspicious beginning, and we believe that continued scientific conclusions of magnesium’s role in blood pressure support will be understood and embraced by both industry and consumers.” Cohen added that there are many compelling studies published associating magnesium with managing vascular calcification, the state of which affects blood pressure.1 He elucidated, “We believe that in the future more evidence will arise showing full support about the help of magnesium for blood pressure reduction. Some supportive or suggested mechanism that needs to be checked and verified is the theory that magnesium may prevent inner walls calcification of the arteries. We believe that checking this mechanism may show that the arteries remain more flexible and expendable and therefore blood pressure may be reduced. We have not found clear evidence of this theory, however, our intensive work with this mineral can point out that this mechanism may be feasible.” GBI offers a range of magnesium raw materials including magnesium citrate, magnesium gluconate, magnesium phosphate, GadoMag K, GadoMag+, and Cal2Mag. GBI provides R&D with a range of non-GMO proprietary products to address a variety of solutions such as solubility in fortified Calcium and Magnesium products without sedimentation or coagulation, tablet grade ingredients for ease of manufacturing supplements, and micronization options for mouth feel and clear liquids. With broad experience in developing innovative products tailored to the unique applications of each customer, Gadot Biochemical Industries, a leading GMP manufacturer of ingredients for the nutraceutical, industrial, food, beverage and pharmaceutical industries has earned a worldwide reputation for producing high quality bioavailable products. Gadot has more than 50 years of experience delivering high bioavailable products including tailor-made solutions and soluble minerals. Over 95% of Gadot’s production is exported worldwide to leading companies in the food, beverage, and nutraceutical industries. For more information visit www.gadotbio.com. For technical assistance contact contact@gadotbio.com
Site by Imaginet
Privacy Policy Ⓒ All rights reserved to GBi

Accessibility Toolbar